 |
|
Growth Hormone–Releasing Hormone in HIV-Infected Men With Lipodystrophy
A Randomized Controlled Trial
Polyxeni Koutkia, MD, MA;
Bridget Canavan, BA;
Jeff Breu, BS;
Martin Torriani, MD;
John Kissko, MS;
Steven Grinspoon, MD
JAMA. 2004;292:210-218.
Context Reduced growth hormone (GH) concentrations are observed in men with human immunodeficiency virus (HIV) lipodystrophy.
Objective To investigate the effects of growth hormone–releasing hormone (GHRH), a GH secretagogue, in treatment of HIV lipodystrophy.
Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial conducted at a research center in the United States between October 2002 and June 2003 and enrolling 31 HIV-infected men aged 18 to 60 years with evidence of lipodystrophy.
Interventions Participants were assigned to receive GHRH (1 mg subcutaneously twice daily) or placebo for 12 weeks.
Main Outcome Measures The primary outcome was change in concentrations of insulin-like growth factor 1 (IGF-1) to detect overall change in GH levels in response to GHRH. Secondary end points included body composition by dual-energy x-ray absorptiometry and computed tomography, lipodystrophy ratings, and levels of glucose, insulin, and lipids.
Results Mean (SD) IGF-1 concentrations increased significantly in the GHRH group vs the placebo group (104 [110] ng/mL vs 6 [44] ng/mL, P = .004). Lean body mass significantly increased in the GHRH group vs the placebo group (0.9 [1.3] kg vs –0.3 [1.7] kg, P = .04), trunk fat significantly decreased (–0.4 [0.7] kg vs 0.2 [0.6] kg, P = .03), and the ratio of trunk to lower extremity fat improved significantly (–0.22 [0.32] vs 0.14 [0.29], P = .005). Abdominal visceral fat was reduced (–19.2 [36.6] cm2 vs 2.3 [24.3] cm2, P = .07) and the ratio of abdominal visceral fat to abdominal subcutaneous fat improved significantly more in the GHRH group (–0.19 [0.28] vs 0.07 [0.27], P = .02). Both physician and patient rating of lipodystrophy in the arms, legs, and abdomen also improved significantly. Levels of glucose, insulin, and lipids did not change significantly.
Conclusions GHRH was well tolerated and effectively increased levels of IGF-1 in HIV-infected men with lipodystrophy. Total and regional body composition improved in response to GHRH, with increased lean mass and reduced truncal and visceral fat. Use of GHRH may potentially be a beneficial treatment strategy for this population.
Author Affiliations: Massachusetts General Hospital Program in Nutritional Metabolism and Neuroendocrine Unit (Drs Koutkia and Grinspoon, Ms Canavan) and Department of Radiology (Dr Torriani and Mr Kissko), Harvard Medical School, Boston, Mass; General Clinical Research Center, Massachusetts Institute of Technology, Cambridge (Mr Breu).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection
Samaras
J Antimicrob Chemother 2008;61:238-245.
ABSTRACT
| FULL TEXT
Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV
Falutz et al.
NEJM 2007;357:2359-2370.
ABSTRACT
| FULL TEXT
Manipulation of the Growth Hormone Axis in Patients with HIV Infection
Blackman
NEJM 2007;357:2397-2399.
FULL TEXT
Effects of Testosterone Therapy on Cardiovascular Risk Markers in Androgen-Deficient Women with Hypopituitarism
Miller et al.
J. Clin. Endocrinol. Metab. 2007;92:2474-2479.
ABSTRACT
| FULL TEXT
Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome
D'Amico et al.
Am. J. Clin. Nutr. 2006;84:204-211.
ABSTRACT
| FULL TEXT
Effects of Testosterone Replacement in Androgen-Deficient Women with Hypopituitarism: A Randomized, Double-Blind, Placebo-Controlled Study
Miller et al.
J. Clin. Endocrinol. Metab. 2006;91:1683-1690.
ABSTRACT
| FULL TEXT
Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults
Teichman et al.
J. Clin. Endocrinol. Metab. 2006;91:799-805.
ABSTRACT
| FULL TEXT
Central Fat Excess in Polycystic Ovary Syndrome: Relation to Low-Grade Inflammation and Insulin Resistance
Puder et al.
J. Clin. Endocrinol. Metab. 2005;90:6014-6021.
ABSTRACT
| FULL TEXT
Provision or Distribution of Growth Hormone for "Antiaging": Clinical and Legal Issues
Perls et al.
JAMA 2005;294:2086-2090.
FULL TEXT
Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease
Troosters et al.
Am. J. Respir. Crit. Care Med. 2005;172:19-38.
FULL TEXT
Therapeutic approaches to combating lipoatrophy: do they work?
Martin and Mallon
J Antimicrob Chemother 2005;55:612-615.
ABSTRACT
| FULL TEXT
Effects of Growth Hormone-Releasing Hormone on Bone Turnover in Human Immunodeficiency Virus-Infected Men with Fat Accumulation
Koutkia et al.
J. Clin. Endocrinol. Metab. 2005;90:2154-2160.
ABSTRACT
| FULL TEXT
Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults
Grinspoon and Carr
NEJM 2005;352:48-62.
FULL TEXT
Growth Hormone-Releasing Hormone for HIV-Related Lipodystrophy
JWatch Infect. Diseases 2004;2004:4-4.
FULL TEXT
|
